Science

Scientists Identify Enzyme That Accelerates Aging Without Triggering Inflammation

Researchers identified an enzyme that accelerates tissue ageing without triggering inflammation, offering a new target for anti‑ageing therapies.

S
SciTech Editorial Team
Newsroom
··1 min read
Scientists Identify Enzyme That Accelerates Aging Without Triggering Inflammation
A multinational research team led by Dr. D. Kannangara has pinpointed an enzyme that drives ageing in body tissues while leaving the immune system untouched. Published in Nature in October 2026, the study shows that genetically disabling this enzyme in mice markedly reduces liver stiffening and scar formation, offering a proof‑of‑concept that ageing can be decelerated without provoking inflammation. The investigators used CRISPR‑based gene editing to knock out the gene encoding the enzyme, termed AGE‑X (Age‑Driving Enzyme). Within eight weeks, the engineered mice displayed a 30 % drop in hepatic rigidity measured by shear‑wave elastography, and histological analysis revealed a 40 % reduction in collagen deposition. Crucially, flow cytometry confirmed that circulating immune cell counts and cytokine profiles remained comparable to wild‑type controls, indicating that immune surveillance was not compromised. "This discovery opens a therapeutic window to lower AGE‑X levels without eroding the body's defensive arsenal," said Dr. Kannangara in an interview. The enzyme appears to amplify a non‑inflammatory signalling cascade that up‑regulates extracellular‑matrix proteins, thereby accelerating tissue fibrosis and functional decline. By targeting this pathway, drugs could potentially mitigate age‑related organ stiffening while preserving immune competence. The broader implications span geriatric medicine, hepatology, and metabolic health. If similar effects translate to humans, AGE‑X inhibitors could become a cornerstone in treating liver fibrosis, pulmonary stiffening, and even cardiovascular rigidity—conditions that currently lack disease‑modifying therapies. Yet challenges remain: designing small‑molecule inhibitors that are both selective and safe, and navigating the rigorous clinical‑trial pipeline. The team has already secured funding for Phase I trials slated for 2028, in collaboration with biotech firms in the United States and Europe. Success would mark a paradigm shift, positioning ageing‑modulating therapeutics alongside conventional disease‑specific drugs, and could dramatically extend healthspan for millions worldwide.

Share

More from this section: Science